Mitteilungen des Arbeitskreises der Chefärzte und Chefärztinnen von Kliniken für Psychiatrie und Psychotherapie an Allgemeinkrankenhäusern in Deutschland (ACKPA)

Karl H. Beine

doi:10.1055/s-0033-1359971

Psychiatrische Praxis, Inhaltsverzeichnis

Psychiatr Prax 2014; 41(01): 55-56
DOI: 10.1055/s-0033-1359971

Mitteilungen der ACKPA

Mitteilungen des Arbeitskreises der Chefärzte und Chefärztinnen von Kliniken für Psychiatrie und Psychotherapie an Allgemeinkrankenhäusern in Deutschland (ACKPA)

Karl H. Beine

Hamm

Literatur
1 Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 2005; 330: 385-389
2 Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 2006; 26: 203-207
3 Khan A, Khan S, Kolts R et al. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160: 790-792
4 Khan A, Khan SR, Leventhal RM et al. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol 2001; 4: 113-118
5 Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry 2000; 57: 311-317
6 Fergusson D, Doucette S, Glass KC et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005; 330: 396-402
7 Storosum JG, van Zwieten BJ, van den Brink W et al. Suicide risk in placebo-controlled studies of major depression. Am J Psychiatry 2001; 158: 1271-1275
8 Gibbons RD, Hur K, Brown CH et al. Benefits from antidepressants synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69: 572-579
9 Gibbons RD, Brown CH, Hur K et al. Suicidal thoughts and behavior with antidepressant treatment reanalysis of the ran-domized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012; 69: 580-587
10 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
11 DGPPN, BÄK, KBV, AWMF, AkdÄ, BPtK, BApK, DAGSHG, DEGAM, DGPM, DGPs, DGRW (Hrsg) für die Leitliniengruppe Unipolare Depression. S3-Leitlinie/Nationale Versorgungs-Leitlinie Unipolare Depression. 1.. Auflage Berlin, Düsseldorf: DGPPN, ÄZQ, AWMF; 2009. Internet: www.dgppn.de www.versorgungsleitlinien.de www.awmf-leitlinien.de